Digest Network Come funziona
Network
/
Società
An
Non verificato

Anebulo Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMaterie primeMedicina - VarieSalute

16 comunicati stampa

Guarda tutti i comunicati
12/02/2026
Farmaceutica
Salute
Materie prime
Mercato azionario
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/02/2026
Salute
Materie prime
Medicina - Varie
Sanità
Farmaceutica
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Materie prime
Farmaceutica
Sanità
Salute
Medicina - Varie
Finanza
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/01/2026
Salute
Materie prime
Sanità
Farmaceutica
Biotecnologia
Titoli e azioni
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
22/12/2025
Finanza
Salute
Materie prime
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Salute
Farmaceutica
Mercato azionario
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/09/2025
Finanza
Igiene alimentare
Medicina - Varie
Associazioni/Professionisti
Sanità
Farmaceutica
Salute
Materie prime
Mercato azionario
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/09/2025
Industria
Biotecnologia
Materie prime
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/09/2025
Biotecnologia
Materie prime
Farmaceutica
Salute
Medicina - Varie
Sanità
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/07/2025
Farmaceutica
Salute
Materie prime
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
Fonte
Anebulo Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0